Tizoxanide is primarily used as an antiparasitic agent, particularly effective against a range of protozoal and helminthic infections. It is commonly applied in the treatment of giardiasis, an intestinal infection caused by the parasite Giardia lamblia, which leads to symptoms like diarrhea, abdominal pain, and nausea. The compound works by inhibiting the growth and replication of the parasite, thereby aiding in the resolution of the infection.

In addition to giardiasis, tizoxanide has shown efficacy in treating cryptosporidiosis, another parasitic infection that affects the intestines, often seen in immunocompromised patients such as those with HIV/AIDS. Its broad-spectrum antiparasitic activity makes it a valuable option in regions where these infections are prevalent.

Tizoxanide is also being explored for its potential antiviral properties. Research indicates that it may inhibit the replication of certain viruses, including influenza and rotavirus, suggesting its possible use in managing viral infections. However, these applications are still under investigation and not yet widely adopted in clinical practice.

The compound is typically administered orally, often in the form of a suspension or tablet, making it convenient for patient use. Its safety profile and effectiveness in treating parasitic infections have established it as a significant therapeutic agent in the field of infectious diseases.